Department of Dermatology, Mugla Sıtkı Kocman University Faculty of Medicine, Mugla, Turkey.
Department of Dermatology, Mugla Sıtkı Kocman University Training and Research Hospital, Mugla, Turkey.
Dermatol Ther. 2019 Sep;32(5):e13044. doi: 10.1111/dth.13044. Epub 2019 Aug 20.
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit. Dermcidin (DCD) is an antimicrobial peptide released from eccrine sweat glands and sebaceous glands. Studies investigating the role of DCD expression in acne development are scarce. The aim of this study was to determine the relationship between DCD expression and acne vulgaris and the effect of oral isotretinoin treatment on DCD levels. Two groups (one patient group and one control group) were included in the study. The patient group consisted of 30 patients with acne vulgaris who were given oral isotretinoin treatment for 6 months until the cumulative dose was attained. Plasma DCD levels were investigated before and 6 months after treatment. The control group comprised 30 volunteer individuals without acne vulgaris or any inflammatory dermatosis. Of the patients, 24 (80%) had Grade 3, 3 (10%) had Grade 1, and 3 (10%) had Grade 4 acne vulgaris, as determined according to the Pillsbury scoring method. The DCD levels in the control group were significantly higher than those in pretreatment patients (39.53 ± 20.2 vs. 28.60 ± 20.12, p = .004). Additionally, pretreatment DCD levels were significantly increased after 6 months of isotretinoin treatment in the patient group (28.60 ± 20.12 vs. 35.07 ± 24.02, p = .012). The mean pretreatment global acne grading system score of 20.86 ± 4.43 was decreased to 5.17 ± 1.91 in patients after treatment (p < .001). This study indicated that DCD plays an important role in the pathogenesis of acne. It demonstrates anti-inflammatory properties in acne vulgaris. Moreover, it was shown that isotretinoin treatment may improve acne vulgaris by increasing DCD levels.
寻常痤疮是一种毛囊皮脂腺单位的慢性炎症性疾病。皮脂素（DCD）是一种从顶泌汗腺和皮脂腺释放的抗菌肽。研究 DCD 表达在痤疮发病机制中的作用的研究很少。本研究旨在确定 DCD 表达与寻常痤疮的关系，以及口服异维 A 酸治疗对 DCD 水平的影响。本研究纳入了两组（一组为患者组，一组为对照组）。患者组由 30 例患有寻常痤疮的患者组成，他们接受了 6 个月的口服异维 A 酸治疗，直至累积剂量达到。在治疗前和治疗 6 个月后检测血浆 DCD 水平。对照组由 30 名无寻常痤疮或任何炎症性皮肤病的志愿者组成。根据 Pillsbury 评分法，患者中 24 例（80%）为 3 级，3 例（10%）为 1 级，3 例（10%）为 4 级寻常痤疮。对照组的 DCD 水平明显高于治疗前的患者（39.53±20.2 与 28.60±20.12，p=0.004）。此外，患者组在异维 A 酸治疗 6 个月后，DCD 水平明显升高（28.60±20.12 与 35.07±24.02，p=0.012）。治疗前患者的总痤疮分级系统评分平均值为 20.86±4.43，治疗后降至 5.17±1.91（p<0.001）。本研究表明，DCD 在痤疮发病机制中起重要作用。它在寻常痤疮中具有抗炎作用。此外，研究表明，异维 A 酸治疗可能通过增加 DCD 水平来改善寻常痤疮。
